Pushing on with Pixuvri

Cell Therapeutics Inc. has raised more than $1 billion since its inception in 1992, including almost $350 million in the two years since the company stopped a Phase III trial of Pixuvri pixantrone because of difficulty enrolling enough patients with aggressive non-Hodgkin's lymphoma. After this setback, the company was handed a complete response letter last month in which FDA asked for another trial.

The company and its investors are prepared to press forward...